secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001628280-23-034547
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals appoints industry veteran R. Keith Woods to Board of Directors
--------------------------------------------------------------------------------

- Woods appointed as independent Class II director effective Oct 16, 2023, term through 2025 annual meeting.
- He brings 30+ years life science experience, most recently COO of argenx, leading rare disease global launch.
- Received initial equity award of 90,000 RSUs vesting equally over 3 years; accelerated on change of control.
- No family relationships or material interests with directors/officers; standard indemnification agreement entered.
- Appointment follows recent U.S. regulatory submission of X4's first drug candidate (mavorixafor) for WHIM syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/0001628280-23-034547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/xfor-20231016.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer